1800 El Camino Real
Suite D
Menlo Park, CA 94027
United States
650 331 9090
https://www.an2therapeutics.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 41
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Joseph S. Zakrzewski | Co-founder & Chairman of the Board | 76,5k | N/A | 1962 |
Mr. Eric E. Easom | Co-founder, CEO, President & Director | 920k | N/A | 1968 |
Dr. Paul Eckburg M.D. | Chief Medical Officer | 688,2k | N/A | 1970 |
Dr. George Harrison Talbot FACP, M.D. | Co-Founder & Senior Clinical Advisor | N/A | N/A | 1948 |
Dr. Michael R. K. Alley Ph.D. | Co-Founder & Head of Biology | N/A | N/A | N/A |
Dr. Sanjay Chanda Ph.D. | Chief Development Officer | N/A | N/A | 1965 |
Mr. Kevin Krause B.S., M.B.A. | Chief Strategy Officer | N/A | N/A | 1975 |
Ms. Jennifer Huber | Senior Vice President of Regulatory Affairs & Quality | N/A | N/A | N/A |
Ms. Annie Yoshiyama | VP of Finance & Corporate Controller | N/A | N/A | 1984 |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.